Esat Quiz On C1 Vaf

15 Questions | Total Attempts: 145

SettingsSettingsSettings
Please wait...
Friday The 13th Quizzes & Trivia

Dear Colleagues, Welcome to the 1st E-Sat quiz for the month of February on C1 VAF. This quiz will be open from 11. 00 pm on Wednesday( 6th February 2013) till the 13th of February( Tuesday) 11. 45 pm. The time limit for this quiz is 15 minutes & only one attempt per user. Wish you all the very best !


Questions and Answers
  • 1. 
    Benefits of HDPE 
    • A. 

      Protection from Disease causing Germs

    • B. 

      Protection from Sunlight, Moisture and temperature changes .

    • C. 

      Protection from Clavulanic acid getting evaporated

    • D. 

      Packing Looks good and unbreakable

  • 2. 
    Dispersibility can increase ______________ Cefpodoxime.
    • A. 

      Bioavailability

    • B. 

      MIC

    • C. 

      Half Life

    • D. 

      Shelf Life

  • 3. 
    Ofloxacin in Finecef-O 
    • A. 

      Reduces toxins in liver

    • B. 

      Increase toxins in liver

    • C. 

      Reduces Toxin damage in Lungs

    • D. 

      Increase toxin damage in Lungs

  • 4. 
    Shelf Life of Fightox?
    • A. 

      42 months

    • B. 

      24 months

    • C. 

      12 months

    • D. 

      21 months

  • 5. 
    Advantage of Cefi-L over Quinolone monotherapy ?
    • A. 

      Narrow spectrum coverage hence superior bacterial eradication

    • B. 

      No spectrum coverage hence superior bacterial eradication

    • C. 

      Broad spectrum coverage hence superior bacterial eradication

    • D. 

      Brand spectrum coverage hence superior bacterial eradication

  • 6. 
    Cefi-XL offers excellent activities against ________ & _________
    • A. 

      S. Pyogenes & S. Pneumoniae

    • B. 

      S. Pyogenes

    • C. 

      S. Pneumoniae

    • D. 

      None of the above

  • 7. 
    ___________ recommends amoxyclav  ( FIGHTOX) as 1st line in sinusitis
    • A. 

      Journal of Antimicrobial Chemotherapy

    • B. 

      Bio Med Center

    • C. 

      Infectious Disease Society of America

    • D. 

      European Respiratory Guidelines

  • 8. 
    In Cefi-XL the pH dependent release of Lactic acid bacillus ensures......?
    • A. 

      Protection against Antibiotic Associated Diarrhea

    • B. 

      Inhibition G_ve bacteria

    • C. 

      Inhibition G+ve bacteria

    • D. 

      Inhibition of Atypical bacteria

  • 9. 
    Cefi-O study published in Indian Medical Gazzete in 2010 has trials conducted on ______?
    • A. 

      2000 patients across 1000 centers

    • B. 

      1000 patients across 572centres

    • C. 

      1572 patients across 1000 centers

    • D. 

      1000 patients across 1000 centers

  • 10. 
    Recent MIC study conducted on Cefi-O was done on ________ pathogens ?
    • A. 

      Salmonella Typhi

    • B. 

      E coli

    • C. 

      Klebsiella Pneumonia

    • D. 

      All of the above

  • 11. 
    __________recommends Cefixime as emperical therapy in childrens suffering from typhoid fever ?
    • A. 

      Indian Academy of Physicians

    • B. 

      Indian Association of Pediatrics

    • C. 

      Indian Academy of Pediatrics

    • D. 

      Indian Association of Physicians

  • 12. 
    Amoxyclav helps in healing wounds published in  
    • A. 

      Journal of Antimicrobial Chemotherapy

    • B. 

      Journal of Wounds

    • C. 

      Journal of Physicians

    • D. 

      Journal of Microbial therapy

  • 13. 
    Anafortan offers superior safety profile with less Anticholinergic side effects like
    • A. 

      Hypersensitivity

    • B. 

      Gastritis

    • C. 

      Dizziness and Dryness of mouth

    • D. 

      None of the above

  • 14. 
    Percentage of Patients got relief from pain in Intestinal colic with Anafortan Inj
    • A. 

      71%

    • B. 

      81%

    • C. 

      91%

    • D. 

      101%

  • 15. 
    Competitor of Anafortan Tab
    • A. 

      Meftal Spas

    • B. 

      Cyclopam

    • C. 

      Spasmoproxyvon

    • D. 

      All of the above

Back to Top Back to top